Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Kim SJ, Nakayama S, Shimazu K, Tamaki Y, Akazawa K, Tsukamoto F, Torikoshi Y, Matsushima T, Shibayama M, Ishihara H, Noguchi S. Kim SJ, et al. Among authors: matsushima t. Ann Oncol. 2012 Apr;23(4):891-7. doi: 10.1093/annonc/mdr340. Epub 2011 Aug 4. Ann Oncol. 2012. PMID: 21821547 Free article. Clinical Trial.
A new cancer diagnostic system based on a CDK profiling technology.
Ishihara H, Yoshida T, Kawasaki Y, Kobayashi H, Yamasaki M, Nakayama S, Miki E, Shohmi K, Matsushima T, Tada S, Torikoshi Y, Morita M, Tamura S, Hino Y, Kamiyama J, Sowa Y, Tsuchihashi Y, Yamagishi H, Sakai T. Ishihara H, et al. Among authors: matsushima t. Biochim Biophys Acta. 2005 Sep 25;1741(3):226-33. doi: 10.1016/j.bbadis.2005.06.001. Biochim Biophys Acta. 2005. PMID: 15990281 Free article.
Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients.
van Nes JG, Smit VT, Putter H, Kuppen PJ, Kim SJ, Daito M, Ding J, Shibayama M, Numada S, Gohda K, Matsushima T, Ishihara H, Noguchi S, van de Velde CJ. van Nes JG, et al. Among authors: matsushima t. Br J Cancer. 2009 Feb 10;100(3):494-500. doi: 10.1038/sj.bjc.6604870. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156146 Free PMC article.
Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells.
Nakayama S, Torikoshi Y, Takahashi T, Yoshida T, Sudo T, Matsushima T, Kawasaki Y, Katayama A, Gohda K, Hortobagyi GN, Noguchi S, Sakai T, Ishihara H, Ueno NT. Nakayama S, et al. Among authors: matsushima t. Breast Cancer Res. 2009;11(1):R12. doi: 10.1186/bcr2231. Epub 2009 Feb 24. Breast Cancer Res. 2009. PMID: 19239702 Free PMC article.
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, Nakayama S, Gohda K, Friess H, van de Velde CJ, Ishihara H, Rosenberg R, Kuppen PJ, Janssen KP. Zeestraten EC, et al. Among authors: matsushima t. Br J Cancer. 2012 Jan 3;106(1):133-40. doi: 10.1038/bjc.2011.504. Epub 2011 Nov 22. Br J Cancer. 2012. PMID: 22108518 Free PMC article.
The prognostic value of apoptotic and proliferative markers in breast cancer.
Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ, Kuppen PJ. Engels CC, et al. Among authors: matsushima t. Breast Cancer Res Treat. 2013 Nov;142(2):323-39. doi: 10.1007/s10549-013-2748-y. Epub 2013 Nov 6. Breast Cancer Res Treat. 2013. PMID: 24194179
Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient.
Torikoshi Y, Gohda K, Davis ML, Symmans WF, Pusztai L, Kazansky A, Nakayama S, Yoshida T, Matsushima T, Hortobagyi GN, Ishihara H, Kim SJ, Noguchi S, Ueno NT. Torikoshi Y, et al. Among authors: matsushima t. J Cancer. 2013 Nov 14;4(9):697-702. doi: 10.7150/jca.6248. eCollection 2013. J Cancer. 2013. PMID: 24312139 Free PMC article.
CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence.
Hongo F, Takaha N, Oishi M, Ueda T, Nakamura T, Naitoh Y, Naya Y, Kamoi K, Okihara K, Matsushima T, Nakayama S, Ishihara H, Sakai T, Miki T. Hongo F, et al. Among authors: matsushima t. Urol Oncol. 2014 Nov;32(8):1240-6. doi: 10.1016/j.urolonc.2014.05.006. Epub 2014 Nov 14. Urol Oncol. 2014. PMID: 25443276 Free article.
1,396 results